XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution
October 12, 2023 07:00 ET
|
XORTX Therapeutics Inc.
ISS, a leading proxy advisory firm, recommends XORTX Therapeutics Inc.’s shareholders vote FOR the share consolidation resolution, stating that approving the share consolidation will “enhance the...
XORTX Calls Special Meeting of Shareholders
October 04, 2023 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Oct. 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023
September 28, 2023 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 28, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Participation at Upcoming Investor Conferences
September 11, 2023 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Sept. 11, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Joins the Kidney Foundation and Kidney March
September 07, 2023 07:00 ET
|
XORTX Therapeutics Inc.
● In Support of Research for Treating the 4 Million Canadians Who Have Chronic Kidney Disease Today ● CALGARY, Alberta, Sept. 07, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the...
XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease
August 29, 2023 07:00 ET
|
XORTX Therapeutics Inc.
● XORTX’s Proprietary Formulation of Oxypurinol – XORLO™ – to Treat Progressive Kidney Disease Associated with Autosomal Dominant Polycystic Kidney Disease (ADPKD) ● CALGARY, Alberta, Aug. 29, 2023 ...
XORTX Appoints Chief Financial Officer
August 04, 2023 17:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, Aug. 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Announces Results of Annual and Special Meeting of Shareholders
June 29, 2023 08:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, June 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company’s Upcoming Annual and Special Meeting of Shareholders
June 23, 2023 20:51 ET
|
XORTX Therapeutics Inc.
The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26, 2023. XORTX’s board of directors recommends shareholders vote FOR the...
XORTX Announces PKD Presentation
June 06, 2023 07:00 ET
|
XORTX Therapeutics Inc.
CALGARY, Alberta, June 06, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...